Received Mar 19, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TYP | TYPHOID LIVE ORAL TY21A (VIVOTIF) | BERNA BIOTECH, LTD. | 3 | 3004333 | PO / MO |
The patient missed the fourth dose of Vivotif; Case reference number US-BN-2025-001095 is a spontaneous case initially received from consumer via Med Communication (reference number: USBAV25-1470) on 19-Jun-2025 and concerns a 17-years-old female patient. The patient's medical history and concomitant medication details were not provided. On 04-Jun-2025, the patient took first dose of Vivotif (batch number: 3004333) orally, at unknown dose, for indication typhoid immunization. On 06-Jun-2025, two days after first dose, the patient took second dose of Vivotif (batch number: 3004333) orally, at unknown dose. On 08-Jun-2025, two days after second dose, the patient took third dose of Vivotif (batch number: 3004333) orally, at unknown dose. As reported, the patient took Vivotif in the [withheld] before going to [withheld] and missed the fourth dose (explicitly coded as 'missed dose'). Now the patient was in [withheld] and would like to know whether or not should take the last dose when returns, which was about 13 days after was supposed to take the last dose. At the time of the initial report, it was unknown if patient experienced any adverse event due to Vivotif. No further information provided.; Reporter's Comments: A 17-year-old female patient missed the fourth dose of Vivotif for indication typhoid immunization, which is considered as missed dose. It was unknown if patient experienced any adverse event due to Vivotif. Product dose omission issue is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Product dose omission issue is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.; Sender's Comments: A 17-year-old female patient missed the fourth dose of Vivotif for indication typhoid immunization, which is considered as missed dose. It was unknown if patient experienced any adverse event due to Vivotif. Product dose omission issue is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Product dose omission issue is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.
Comments: None.